• Trials and Research

  Ozanimod Lowers Relapse Rates in Patients with MS

  Posted by MS News Today Moderator on August 9, 2018 at 7:33 am

  Data from a 2-year extension of a Phase 2 trial shows that continuous treatment with oral ozanimod consistently reduced disease activity in RRMS patients.

  Read more about this study and its findings here.

  What do you think about this news?

  replied 5 years, 8 months ago 1 Member · 0 Replies
• 0 Replies

Log In to Reply